echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Review of Nifedipine Sustained Release Tablets (II), a subsidiary of China Resources Double Crane

    Review of Nifedipine Sustained Release Tablets (II), a subsidiary of China Resources Double Crane

    • Last Update: 2021-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 7, China Resources Double-Crane issued an announcement stating that the subsidiary had received the Nifedipine Sustained-Release Tablets (II) "Drug Supplementary Application Approval Notice" approved and issued by the State Food and Drug Administration.


    The drug mainly treats chronic stable angina pectoris (worked angina pectoris), vasospasm angina pectoris (Prinzmetal's angina pectoris, variant angina pectoris) and essential hypertension.


    As of the date of this announcement, Shuanghe Limin has invested RMB 8.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.